With its ever-expanding legalization, marijuana has gained mainstream acceptance. But do we really know it’s safe? asks Hannah Wallace.
Last year, Oregon became the fourth state to legalize the recreational use of marijuana. In my hometown of Portland, people began lighting up on street corners, friends threw pot-themed dinner parties, and I heard whispers about a chef who hand-delivers salted caramel medibles (medical-cannabis edibles).
Whenever my husband, an unapologetic marijuana enthusiast, invites me to join him, I decline. Past experiments always gave me a sense of creeping agitation rather than euphoria. I struggle with insomnia, however, and my cocktail of remedies—valerian, wine, and Ambien—has become less and less reliable. Which is how I find myself one recent afternoon at Farma, a dispensary a mile from my house, admiring buds with names like Island Sweet Skunk and Dogwalker that are displayed beneath glass like so many exquisite chocolates. “I’m looking for something that will help me sleep—an indica?” I stammer, naming the strain that I’ve read delivers a calming high (another, sativa, has a reputation for working as a stimulant).
“We don’t classify cannabis that way,” my budtender, a slender young beauty, tells me crisply. “It’s the terpenes that are important.” Terpenes, she explains, are the aromatic oily compounds that confer character on each strain of marijuana and are believed to be responsible for particular effects. So while every label at Farma lists the percentages of tetrahydrocannabinol (THC), pot’s main psychoactive compound, and cannabidiol (CBD), the medicinal element that eases pain and anxiety but won’t get you high, terpenes are the ingredient of the moment. My attendant selects a glass jar and waves it under my nose. “I’d try Blueberry Malawi combined with Harlequin,” she cheerfully suggests.
This story is from the December 2016 edition of Vogue.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the December 2016 edition of Vogue.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.
Already a subscriber? Sign In
Quick Change
The promise of color-adaptive beauty products? Your most flattering shade is just a chemical reaction away.
Scent Symphony
The latest mash-up: Cartier x Scriabin. Chloe Schama investigates the ever-expanding fusion of live music and fragrance.
Live at the Apollo
Grammy nominee Omar Apollo is coming into his own.
Family Ties
At the end of her first year as Dior CEO, Delphine Arnault is proving to be a powerful protector of legacy and a leader poised to make waves.
Catch a Fire
You’d be forgiven for not quite knowing where you’ve seen Kingsley Ben-Adir before.
The Menagerie
A childhood in war-torn Kosovo led Petrit Halilaj to make some of the most exuberant, playful contemporary art around. Dodie Kazanjian meets the optimist as he prepares for a major installation at The Metropolitan Museum of Art.
History Lessons
In the new stage adaptation of Henrik Ibsen's An Enemy of the People, Jeremy Strong sees the shadows of current crises.
Tangier Dreams
With its fleet of exciting cultural hubs and smart new hotels, the storied North African city has never been more inspiring to visit.
The End of Glitter?
Or are we just at the beginning—of a new era of microplastic-free, perfectly-healthy-to-eat sparkle. Tamar Adler reports on glitz to feel good about.
Live to Tell
The powerful, engrossing documentary High & Low: John Galliano sees the designer tell the story of his life.